<DOC>
	<DOC>NCT01397890</DOC>
	<brief_summary>This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with severe chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed and dated informed consent Men or women patients ≥40 years of age Diagnosis of COPD with symptoms for more than 2 years and there is a history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 112 months before Visit 2 Forced Expiratory Volume in 1 second (FEV1) ≤50% of predicted normal value, prebronchodilator and Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) &lt; 70%, prebronchodilator Total symptom score of 2 or more per day for at least half of runin period (breathing, cough and sputum scores from the diary card) and complete morning recordings of Digital Peak Flow Meter data at least 7 out of the last 10 days of the runin period A history of asthma and seasonal allergic rhinitis before 40 years of age Patients who have experienced exacerbation of COPD requiring hospitalisation and /or emergency room treatment and/or a course of oral steroids and/or intravenous corticosteroids and/or antibiotics within 4 weeks prior to Visit 2 and/or during runin period and also the patients who use of systemic glucocorticosteroids (GCS) within 4 weeks and/or inhaled GCS within 2 weeks prior to Visit 2 and/or during runin period Patients with relevant cardiovascular disorder judged by the investigator Patients with glaucoma, prostatic hyperplasia or bladderneck obstruction judged by the investigator Women who are pregnant, breastfeeding or of childbearing potential judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Severe chronic obstructive pulmonary disease (COPD) patients</keyword>
</DOC>